Clinical Trial Update: Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)

View source ↗

Summary

This is a completed non-interventional postauthorization safety study evaluating Ventavis (iloprost) for pulmonary arterial hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Ventavis (iloprost)

Snippet

Sponsor: Bayer | Conditions: Hypertension, Pulmonary | Status: COMPLETED